CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue
Housing	$ 0	$ 0	$ 0	$ 141,953
Commercial rental - related party	0	0	0	0
Tissue array products	132,941	129,032	422,820	341,596
Total revenue	132,941	129,032	422,820	483,549
Cost of Sales
Housing	0	0	0	123,091
Commercial rental - related party	182	16,140	21,444	49,235
Tissue array products	96,747	77,895	280,082	222,329
Total cost of sales	96,929	94,035	301,526	394,655
Gross Profit	36,012	34,997	121,294	88,894
Operating Expenses:
Salaries and wages	82,085	51,279	178,048	153,839
Depreciation and amortization	23,992	37,264	63,428	112,272
Estimates of loss contingencies	0	(37,910)	0	(37,910)
Professional fees	11,547	28,529	66,111	66,264
Selling and distribution expenses	1,622	1,370	7,726	4,123
Other general and administrative expenses	7,572	47,305	149,279	129,373
Total Operating Expenses	126,818	127,837	464,592	427,961
Loss from Operations	(90,806)	(92,840)	(343,298)	(339,067)
Other Income (Expense)
Interest expenses	(66,564)	(39,284)	(174,362)	(131,406)
Other income (expense), net	(2,931)	(2,567)	21,635	(25,128)
Total Other Expense, Net	(69,495)	(41,851)	(152,727)	(156,534)
Loss before Income Taxes	(160,301)	(134,691)	(496,025)	(495,601)
Income Tax Expense	(104)	(152)	(388)	(314)
Net loss	(160,405)	(134,843)	(496,413)	(495,915)
Less: Net loss attributable to the non-controlling interests	(37,555)	(20,955)	(101,490)	(89,280)
Net loss attributable to CYBRDI, INC.	(122,850)	(113,888)	(394,923)	(406,635)
Foreign currency translation gain	182,387	62,343	178,978	5,914
Comprehensive income (loss)	$ 59,537	$ (51,545)	$ (215,945)	$ (400,721)
Net Loss Per Common Share
Basic and Diluted	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted Average Number of Shares Outstanding
Basic and Diluted	120,225,323	120,225,323	120,225,323	120,225,323